Assenagon Asset Management S.A. Abb Vie Inc. Transaction History

Assenagon Asset Management S.A.

$37.1 Billion
Q1 2024

A detailed history of Assenagon Asset Management S.A. transactions in Abb Vie Inc. stock. As of the latest transaction made, Assenagon Asset Management S.A. holds 317,559 shares of ABBV stock, worth $51.2 Million. This represents 0.16% of its overall portfolio holdings.

Number of Shares

317,559

Previous 2,143,910 85.19%

Holding current value

$51.2 Million

Previous $332 Million 82.59%

% of portfolio

0.16%

Previous 1.03%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 24, 2024	SELL	$159.82 - $182.1 $292 Million - $333 Million	-1,826,351 Reduced 85.19%	317,559 $57.8 Million
Q4 2023 Jan 17, 2024	BUY	$137.6 - $154.97 $197 Million - $222 Million	1,433,236 Added 201.67%	2,143,910 $332 Million
Q3 2023 Nov 06, 2023	BUY	$133.59 - $154.65 $31.2 Million - $36.1 Million	233,403 Added 48.9%	710,674 $106 Million
Q2 2023 Jul 25, 2023	BUY	$132.51 - $164.9 $25 Million - $31.1 Million	188,558 Added 65.31%	477,271 $64.3 Million
Q1 2023 Apr 18, 2023	BUY	$144.61 - $166.54 $5.54 Million - $6.38 Million	38,335 Added 15.31%	288,713 $46 Million

Q4 2022 Jan 12, 2023	SELL	$138.31 - $165.87 $13.5 Million - $16.2 Million	-97,899 Reduced 28.11%	250,378 $40.5 Million
Q3 2022 Oct 27, 2022	SELL	$134.21 - $153.93 $38.6 Million - $44.2 Million	-287,434 Reduced 45.21%	348,277 $46.7 Million
Q2 2022 Jul 27, 2022	SELL	$137.62 - $174.96 $98,535 - $125,271	-716 Reduced 0.11%	635,711 $97.4 Million
Q1 2022 Apr 25, 2022	SELL	$131.98 - $163.75 $23.3 Million - $29 Million	-176,849 Reduced 21.75%	636,427 $103 Million
Q4 2021 Feb 01, 2022	SELL	$107.43 - $135.93 $283 Million - $358 Million	-2,631,894 Reduced 76.39%	813,276 $110 Million
Q3 2021 Oct 19, 2021	BUY	$106.4 - $120.78 $259 Million - $294 Million	2,431,209 Added 239.77%	3,445,170 $372 Million
Q2 2021 Jul 15, 2021	BUY	$105.21 - $117.21 $65.5 Million - $72.9 Million	622,096 Added 158.75%	1,013,961 $114 Million
Q1 2021 Apr 26, 2021	SELL	$102.3 - $112.62 $89.3 Million - $98.3 Million	-872,915 Reduced 69.02%	391,865 $42.4 Million
Q4 2020 Feb 01, 2021	BUY	$80.49 - $108.67 $46.5 Million - $62.8 Million	578,199 Added 84.21%	1,264,780 $136 Million
Q3 2020 Oct 07, 2020	BUY	$85.91 - $100.83 $20.5 Million - $24 Million	238,188 Added 53.12%	686,581 $60.1 Million
Q2 2020 Jul 21, 2020	BUY	$73.37 - $98.18 $18.9 Million - $25.3 Million	257,524 Added 134.92%	448,393 $44 Million
Q1 2020 Apr 17, 2020	BUY	$64.5 - $97.79 $12.3 Million - $18.7 Million	190,869 New	190,869 $14.5 Million
Q3 2019 Oct 16, 2019	SELL	$62.98 - $75.72 $50 Million - $60.2 Million	-794,413 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$65.7 - $83.98 $52.2 Million - $66.7 Million	794,413 New	794,413 $57.8 Million
Q1 2019 Apr 26, 2019	SELL	$77.14 - $90.79 $2.22 Million - $2.61 Million	-28,792 Closed	0 $0
Q4 2018 Jan 23, 2019	SELL	$77.85 - $96.01 $55.9 Million - $68.9 Million	-717,864 Reduced 96.14%	28,792 $2.65 Million
Q3 2018 Oct 29, 2018	BUY	$88.91 - $98.84 $64.5 Million - $71.8 Million	726,012 Added 3516.82%	746,656 $70.6 Million
Q2 2018 Jul 17, 2018	SELL	$89.78 - $106.23 $15.3 Million - $18.1 Million	-170,144 Reduced 89.18%	20,644 $1.91 Million
Q1 2018 Apr 30, 2018	BUY	$92.01 - $123.21 $17 Million - $22.8 Million	184,895 Added 3137.54%	190,788 $18.1 Million
Q4 2017 Jan 25, 2018	SELL	$89.56 - $98.21 $58.8 Million - $64.4 Million	-656,121 Reduced 99.11%	5,893 $570,000
Q3 2017 Oct 18, 2017	BUY	$69.85 - $89.22 $46.2 Million - $59.1 Million	662,014	662,014 $58.8 Million

Others Institutions Holding ABBV

# of Institutions

3,643

Shares Held

1.24B

Call Options Held

15.5M

Put Options Held

11.6M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $285B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assenagon Asset Management S.A., based on Form 13F filings with the SEC.

News

Stay updated on Assenagon Asset Management S.A. with notifications on news.

Account

Assenagon Asset Management S.A. Abb Vie Inc. Transaction History